Background: Sleep disturbance is a common clinical issue for patients with psychosis. It has been identified as a putative causal factor in the onset and persistence of psychotic experiences (paranoia and hallucinations). Hence sleep disruption may be a potential treatment target to prevent the onset of psychosis and reduce persistent psychotic experiences. The aim of this review is to describe developments in understanding the nature, causal role, and treatment of sleep disruption in psychosis. Method: A systematic literature search was conducted to identify studies, published in the last five years, investigating subjective sleep disruption and psychotic experiences. Results: Fifty-eight papers were identified: 37 clinical and 21 non-clinical studies. The studies were correlational (n = 38; 20 clinical, 18 non-clinical), treatment (n = 7; 1 non-clinical), qualitative accounts (n = 6 clinical), prevalence estimates (n = 5 clinical), and experimental tests (n = 2 non-clinical). Insomnia (50%) and nightmare disorder (48%) are the most prevalent sleep problems found in patients. Sleep disruption predicts the onset and persistence of psychotic experiences such as paranoia and hallucinations, with negative affect identified as a partial mediator of this relationship. Patients recognise the detrimental effects of disrupted sleep and are keen for treatment. All psychological intervention studies reported large effect size improvements in sleep and there may be modest resultant improvements in psychotic experiences. Conclusions: Sleep disruption is a treatable clinical problem in patients with psychosis. It is important to treat in its own right but may also lessen psychotic experiences. Research is required on how this knowledge can be implemented in clinical services.
Introduction
"When I'm tired, everything is worse" (Patient with psychosis, Waite et al., 2016a, p.186) Since the first descriptions of schizophrenia sleep dysfunction has been a feature of patient, family, and clinician accounts (see Kraeplin, 1919; Birchwood et al., 1989; Yung and McGorry, 1996) . Despite this, sleep problems have been overlooked as a treatment target. Historically, sleep disruption has been seen as a non-specific epiphenomenon or secondary consequence of a core psychotic disturbance. Over the past ten years there has been increasing interest in a different view: that sleep dysfunction may be a potential causal mechanism in the onset and persistence of psychotic experiences (Anderson and Bradley, 2013; Freeman et al., 2009; Reeve et al., 2015; Soehner et al., 2013; Waters et al., 2017) . This paradigm shift identifies sleep disruption as a potential novel treatment target for psychotic symptoms. It also provides a route to determine causality: if successful treatment of sleep problems results in improvements in psychotic experiences then a causal relationship is demonstrated. Our previous review found that sleep disturbance and psychotic experiences co-occur (Reeve et al., 2015) , but the direction of effect and underlying mechanisms were yet to be established. Given the recent work on sleep and psychosis, particularly treatment innovation, it is timely to review the current status of the evidence and consider the implications for clinical practice.
In patients with psychosis sleep problems are very common. For example, in a survey of 1809 patients with non-affective psychosis attending NHS mental health services, 50.1% had clinically significant levels of insomnia . Disturbances in sleep architecture and circadian systems are also typically found in patients (Cosgrave et al., 2018) . Indeed the clinical picture is complex, with comorbidity of sleep disorders normal rather than the exception (Reeve et al., 2019b) . Patient accounts highlight an interaction between sleep difficulties and psychotic experiences and describe the negative impact on functioning (Faulkner and Bee, 2017; Waite et al., 2016a; Waite et al., 2018) . Clinicians certainly recognise the prevalence and importance of sleep problems, but in current practice formal assessment infrequently occurs and the provision of recommended treatment is extremely limited (Rehman et al., 2017; Reeve et al., 2019b ). Yet there is a clear desire for treatment: three-quarters of patients with psychosis who have insomnia would like treatment to improve their sleep .
In international guidelines the recommended first line treatment for insomnia is cognitive behavioural therapy (CBTi) (for example, National Institute for Health and Care Excellence, 2015; Qaseem et al., 2016; Wilson et al., 2019) . CBTi targets the subjective sleep disturbance which characterises insomnia. It has a well-established evidence base demonstrating effectiveness in treating insomnia (without comorbid psychosis), for example a recent meta-analysis of 87 randomised controlled trials (RCT) found large effect size improvements in selfreported insomnia symptoms (hedges g = 0.98) (van Straten et al., 2018) . In recent years, researchers have begun to investigate the applicability, feasibility, and effectiveness of CBTi in people with psychotic experiences in the general population , individuals at ultra-high-risk of psychosis , patients with persistent psychotic experiences (e.g. Freeman et al., 2015; Hwang et al., 2019; Chiu et al., 2018; ) and patients admitted to acute psychiatric inpatient care . This review aims to provide an overview of sleep disruption and its treatment across this spectrum of psychosis severity. Given previous reviews on the occurrence of sleep disruption and its contribution to psychotic experiences (see Cosgrave et al., 2018; Davies et al., 2017; Reeve et al., 2015) the main focus of this review will be on treatment developments in the past five years. Consistent with treatment guidelines this review will focus on evidence-based psychological interventions. By conducting a literature review of the studies published in the last five years investigating sleep disruption and psychotic experiences, we sought to address the following questions:
1. What is the experience of sleep disruption and its treatment in patients experiencing psychotic symptoms?
2. Do subjective sleep disturbance and psychotic experiences co-occur across this spectrum of psychosis severity? 3. Are psychological interventions for sleep disturbance (CBT) applicable, feasible, and effective on a) subjective sleep problems, b) psychotic experiences?
Method
A search was carried out on PubMed for English language papers published in peer-reviewed journals containing the following terms: ((sleep OR insomnia OR dream* OR nightmare*) AND (Delus* OR Hallucinat* OR Psychosis OR *Schizophren* OR Schizotyp*)), published in the last five years (search conducted on 5th August 2019). Literature on non-human studies was not included. The search criteria were consistent with our earlier review (Reeve et al., 2015) to enable a focus on recent findings.
Both qualitative and quantitative methodologies were included. Papers relating primarily to dementias or other neurological conditions, bipolar disorder, or affective psychoses (including post-partum psychosis) were excluded. Previous reviews were excluded. For quantitative studies, a specific measure of subjective sleep disturbance was required. There are elevated rates of obstructive sleep apnea in patients with psychosis (24%) (see Annamalai et al., 2015) and an established respiratory treatment, however this is outside the scope of this review.
This search revealed 789 papers. Titles and abstracts were scanned, and if appropriate the whole paper, in order to ascertain the inclusion and exclusion criteria. The reference lists of relevant papers were also scanned for further citations, which provided an additional 11 papers. See Fig. 1 for a PRISMA flow diagram of the systematic review process.
Results
Fifty-eight papers were included in the review. Thirty-seven papers concerned clinical samples (8 ultra-high-risk, 3 first-episode psychosis, 22 schizophrenia, 4 acute inpatients) and 21 concerned non-clinical samples. Within the clinical samples there were six qualitative studies, five studies assessed the prevalence of sleep disturbance, 20 studies provided correlational data, and six studies evaluated psychological treatment. In the non-clinical studies, 18 studies provided correlational data, two were manipulation tests, and one study concerned treatment.
3.1. The patient experience of sleep disruption and its treatment "…because, the voices, and there's too many things on your mind and you get anxious and stuff like that but it's...yeah, it is quite hard to get to sleep, it's stressful." (patient 15; Faulkner and Bee, 2017) "When I'm tired it gets worse because I don't have the strength to fight the voices as much". (patient 1; Waite et al., 2016a) Across the spectrum of severity of psychosis there is a striking consistency in patient accounts of the nature of sleep disturbance, the interaction with psychotic experiences, the negative impact on functioning, and treatment preference (Chiu et al., 2016; Bee, 2017, 2016; Waite et al., 2016a; Waite et al., 2018; Waters et al., 2015) .
Patients describe how sleep can be disrupted by psychotic experiences, for example: "if I'm having voices and stuff I find it harder to sleep, my mind's racing" (3, Chiu et al., 2016) ; "These voices like to see me awake and agitated." (13, Faulkner and Bee, 2017) . Patients also highlight the reverse: that sleep problems contribute to the occurrence of psychotic experiences. Indeed, patients describe the reciprocal nature of sleep problems and psychotic experiences as a "nightmare you can't get out of" (4, Waite et al., 2016a) . Yet this also indicates a selfidentified avenue for improvement: "sometimes my voices would be better as well from sleeping" (2, Waite et al., 2016a) . In young people at ultra-high-risk of psychosis, sleep disturbance was typically characterised by disrupted sleep timing . In contrast, patients with persistent psychotic experiences often described being reliant on hypnotic medication or using neuroleptic medication as a route to initiate sleep: "knocking yourself out" (Faulkner and Bee, 2017, p.8) .
Despite wanting better sleep, the accounts highlight a sense of hopelessness and limited expectation concerning treatment outcome. There were often beliefs that sleep simply cannot be changed: "I just seem to be at the mercy of it you know. I just don't really have any control over it really. It's just sometimes it happens for me, and sometimes it doesn't." (5, Chiu et al., 2016) . This sense of resignation was more profound in patients with persistent psychosis, for example: "I know I'm going to be like this forever, there's no point in telling a lie to myself, I know I'll always have problems sleeping" (2, Faulkner and Bee, 2017) . Yet it was already present in many young people at ultra-high-risk of psychosis when offered a sleep intervention: "I didn't think it would work at first" (8, Waite et al., 2018) .
Those patients who had received a psychological sleep intervention described important clinical change and valuing the therapy: "It was really, really good. Really good. I was really impressed. I didn't think it was going to help or anything. I am really impressed" (10, Waite et al., 2016a) . For some, the process of implementing new strategies was challenging: "It's hard to try and change, to try and get myself motivated" (7, Waite et al., 2018 ). Yet, for others, treating sleep problems was identified as a route to improving wider mental health. With some patients explicitly describing an improvement in psychotic symptoms with improved sleep: "since I've been sleeping better, my, visual things have like stopped" (8, Waite et al., 2018) .
The prevalence of sleep disturbance in patients
The patient accounts of sleep disturbance are consistent with the empirical data. Rates of sleep disturbance are elevated across the spectrum of severity of psychotic experiences. Studies indicate that 75-80% of patients at ultra-high-risk (Poe et al., 2017) , those who have experienced a first episode (Ma et al., 2018; Reeve et al., 2019b) , and patients with a diagnosis of schizophrenia (Laskemoen et al., 2019) are experiencing subjective sleep disturbance. There were no studies in the past five years reporting prevalence in acute settings. When specific sleep disorders are assessed using self-report or clinician interview measures the rate of insomnia is approximately 50% Laskemoen et al., 2019) , the rate of weekly nightmares 55% , and the rate of hypersomnia 30% (Laskemoen et al., 2019) in patients with non-affective psychosis. Only one study has conducted formal diagnostic sleep interviews in patients with psychosis (Reeve et al., 2019b) . In a sample of 60 patients with early psychosis, insomnia (50%) and nightmares (48%) were the most common disorders. Sleep disorders were not only highly prevalent but frequently comorbid: the average number of sleep disorders per patient was 3.3 (Reeve et al., 2019b) .
3.3. Sleep disturbance as a causal factor for psychotic experiences
Correlational data
Our previous review found a robust association between sleep dysfunction and psychotic experiences (Reeve et al., 2015) , especially between insomnia and paranoia. The current review found 38 recent studies: 18 general population (Table 1 ) and 20 clinical samples (Table 2) reporting an association between sleep disruption and psychotic experiences.
3.3.1.1. General population studies. The findings from these recent studies robustly confirm the cross-sectional association between sleep dysfunction and psychotic experiences. For example, an analysis of data from over a quarter of a million people in the general population found that insomnia significantly increased the likelihood of reporting at least one psychotic symptom (OR = 2.41; 95% CI 2.18-2.65) (Koyanagi and Stickley, 2015) . In addition to the evidence for insomnia, an online study with 846 participants from the general population found that, even after controlling for PTSD and negative affect, both nightmare occurrence and severity were associated with hallucinatory experiences and paranoia (Rek et al., 2017) .
Several studies provide insight into the temporal relationship using longitudinal and experience sampling method (ESM) designs. For example, in a sample of 4720 young people, nightmares at age 12 predicted psychotic-like experiences (PLE) at age 18 (OR = 1.62, 95% CI 1.19-2.20) (Thompson et al., 2015) . In an ESM study of 61 adolescents, shorter sleep duration predicted paranoia, but paranoid symptoms did not predict sleep parameters (Hennig and Lincoln, 2018) .
Within correlational studies, a number of potential mechanisms have been investigated. For example, an online study with 2678 students found that depression and PTSD symptoms, but not anxiety symptoms, mediated the relationship between poor sleep and PLEs (Ered et al., 2018) . This study examined positive symptoms, but did not report the findings for individual psychotic experiences. Structural equation modelling of a sample of 348 students, recruited in an online study, found an association between subjectively delayed sleep onset and persecutory ideation that was fully mediated by negative affect (Scott et al., 2017) . However there are obvious limitations of cross-sectional mediation analyses (see Maxwell and Cole, 2007) . Mediation tests related to Postal questionnaire (completed by mother) at age2.5, 3.5, 4.75, 6.75, 9 years. Experience of nightmares, night terrors and sleepwalking was assessed using a semi-structured interview at age 12 years.
PLIKSi at age 12 and 18 years.
Nightmares at 12 were a significant predictor of psychotic experiences at 18, remained after adjustment for possible confounders and psychotic experiences at 12 years. Inpatients frequently reported the causes of insomnia to be related to their illness (rather than to their lifestyle factors) and had an incomplete understanding of good sleep habits. nightmares are lacking. However, negative affect and related processes such as worry are candidate variables given their strong associations with nightmare occurrence and severity (Rek et al., 2017) .
Clinical studies.
In patients at ultra-high-risk of psychosis, sleep disruption has been associated with positive and negative symptoms (Lunsford-Avery et al., 2015; Poe et al., 2017) , disrupted cognitive functioning (Lunsford-Avery et al., 2017), severity of psychotic experiences such as hallucinations and delusions (Reeve et al., 2019a) , and overall functioning (Poe et al., 2017) . In a large sample of 740 ultra-high-risk patients, sleep disruption was positively correlated with attenuated psychotic experiences, especially suspiciousness (Goines et al., 2019) . Depression mediated the association between sleep problems and paranoia.
In patients with psychosis, sleep disturbance is associated with poor clinical outcomes (Afonso et al., 2014; Chung et al., 2018; Hou et al., 2017; Kilicaslan et al., 2017; Li et al., 2017) . For example, a naturalistic longitudinal study of 388 patients found that insomnia was associated with an increased risk of suicide attempts (Li et al., 2016) . In the only study specifically reporting correlational data in a first-episode sample, insomnia was associated with poorer outcomes on all four quality of life domains assessed (Subramaniam et al., 2018) .
Only two studies with patients with psychosis reported mediation analyses (Kasanova et al., 2019; Reeve et al., 2018b) . In a longitudinal observational study of 29 patients with non-affective psychosis, insomnia predicted the persistence of psychotic experiences over time: a bidirectional relationship was indicated between insomnia and paranoia however insomnia was found to be a stronger predictor of later hallucinations than the reverse direction (Reeve et al., 2018b ). Mediation models were tested and found that negative affect (anxiety and depression) mediated the relationship between insomnia and psychotic experiences. This is consistent with the findings of an ESM study, in which a time-lagged mixed multilevel model was applied to distinguish the contribution of poor sleep quality on morning paranoia, and evening paranoid ideation on subsequent sleep quality (Kasanova et al., 2019) . Poor sleep quality predicted elevated paranoia, and this was fully mediated by negative affect. However, no significant association was found between evening paranoia and poor sleep quality.
Causal tests
When the amount of sleep is deliberately reduced in experimental manipulation studies, either via total sleep deprivation (Meyhöfer et al., 2017; Petrovsky et al., 2014) or sleep restriction , it results in increases in psychotic experiences. These studies have only been conducted with non-clinical samples, but all three report sleep loss resulting in increased perceptual distortions such as hallucinations. Reeve et al., 2018a also found an increase in paranoia and cognitive disorganisation, but no significant changes in grandiosity. Mediation analyses revealed that changes in psychotic experiences were mediated by changes in negative affect and related processes (including worry and negative self and other cognitions), but not memory impairment. Together these manipulation studies provide strong evidence that sleep disturbance is a contributory cause to paranoia and hallucinatory experiences.
Interventionist-casual tests
"It sorted out my sleep and I'm a better person for it."(patient 10, Waite et al., 2016a, p.187) In the last five years, there have been six intervention studies targeting insomnia and one targeting nightmares (Table 3 ). These studies have typically been designed to not only test whether sleep can be improved but to find out whether psychotic symptoms reduce (an interventionist-causal approach, Kendler and Campbell, 2009 ). Most studies have focused on patients with persistent psychotic symptoms (n = 3 insomnia, n = 1 nightmares). There has been one study conducted in an acute inpatient setting and one with young people at ultra-high-risk of psychosis. However, the most robust finding is provided from a large RCT of university students with insomnia (n = 3755) (OASIS trial; Freeman et al., 2017) .
The goal of the OASIS trial was to definitively test whether there is a causal association between insomnia and paranoia and hallucinations . Students with self-reported insomnia were randomised to receive either a digital CBTi intervention in addition to usual care or usual care alone. Post-treatment, there were large effect size reductions in insomnia (SCI cohen's d = 1.1) and small effect size improvements in paranoia (GPTS-B d = 0.19) and hallucinations (SPEQ-H d = 0.24) in the CBTi group compared with usual care. Those who received the digital sleep treatment were less likely to meet ultrahigh-risk criteria (indicated by a score ≥ 6 on the 16-item prodromal questionnaire) post treatment. Mediation analysis showed that early improvements in sleep (3 weeks) accounted for nearly 60% of the change in paranoia post treatment (10 weeks), with a similar effect found for hallucinations. Parallel analyses in the opposite direction indicated that changes in psychotic experiences explained a much smaller (approx. 3%) proportion of change in sleep. This study provides the most definitive evidence to date that sleep treatment can improve psychotic experiences and that insomnia is a contributory causal factor in paranoia and hallucinations. A key limitation is that the study was not in a clinical population.
In young people at ultra-high-risk, an uncontrolled feasibility case series (SleepWell) with 12 participants (14-24 years) found large effect size improvements in sleep (ISI d = 6.8) following an 8-session individual intervention . The treatment included adaptations to account for the developmental age of participants (for example, including parents, incorporating technology) and the associated circadian phase shifts that occur during adolescence (for example, adjusting expectations of sleep timing). Compared to baseline, the confidence intervals indicated improvements in paranoia (GPTS d = 0.6), hallucinatory experiences (SPEQ-H d = 0.3), and negative affect (DASS-21 depression d = 0.5) post-treatment, yet, as appropriate for pilot studies, the p-values were not reported (for further statistical rationale see Lancaster et al., 2004) . However, the quality of the evidence is limited by the small sample size and lack of control group.
Three studies have evaluated CBTi interventions with patients with persistent psychotic symptoms (two in outpatient settings and one in a residential setting). The Better Sleep Trial (BeST; Freeman et al., 2015) was an assessor-blind pilot randomised controlled trial with 50 patients with current psychotic symptoms. The manualised intervention was delivered on an individual basis over eight sessions. Posttreatment there were large effect size improvements in sleep: 41% of patients in the intervention group no longer had clinical insomnia (compared to 4% in the control group). However, the treatment effect estimation for delusions (PSYRATS d = 0.1 CI −2.0 to 2.6) and hallucinations (PSYRATS d = 0.2, CI −65 to 2.7) included reducing or increasing psychotic experiences. The study was underpowered to determine with any precision the effect on psychotic experiences (which led to the much larger OASIS trial). In addition to the clinical benefits, a health economic evaluation indicated that the sleep intervention may also be cost-effective (Tsiachristas et al., 2018) .
In an open label trial of adapted CBTi added to usual care, compared to usual care alone, differential treatment outcomes were observed between different sleep presentations (Chiu et al., 2018) . Latent class analysis was conducted on the 74 participants to identify three sleep subtypes: classic severe insomnia (44.6%), insomnia with normal sleep duration (37.8%), insomnia with hypersomnia (17.6%). The greatest treatment benefits were observed in the first cluster. In the hypersomnia cluster, total sleep time reduced and sleep onset latency was halved. A blunted treatment response was reported in the normal sleep duration cluster. However, there were comparable improvements in daytime functioning and overall psychopathology. 
Mean sessions
Treatment quality/fidelity standardised due to digitised delivery method.
Significant reductions in sleep disturbance at all timepoints. Post treatment (10 weeks) there were large effect size improvements on the SCI (Cohen's d = 1.11).
Change in sleep at 3 weeks explained 30% of the intervention effect on paranoia at 10 weeks; change in sleep at 10 weeks accounted for 58% of the treatment effect on paranoia.
Change in sleep at 3 weeks explained 21% of the intervention effect on hallucinations post-treatment; change in sleep at 10 weeks accounted for 39% of the intervention effect on hallucinations.
Significant reductions in paranoia and hallucinations at all timepoints. Small effect size changes post treatment for paranoia GPTS-B (d = 0.19) and hallucinations SPEQ-H (d = 0.24).
Improvements in depression (PHQ-9), anxiety (GAD-7), prodromal symptoms (Prodromal questionnaire), nightmares (DDNSI), psychological wellbeing (WEMWBS) and functioning (WSAS) were reported. There was a small increase in mania symptoms (Altman-Mania) in the treatment group.
Bradley et al., 2018
Uncontrolled, feasibility case series of adapted CBTi+TAU.
12 young patients (aged 14-24 years) at ultra-high-risk of psychosis (CAARMS attenuated psychosis criteria) with current sleep problems (≥15 ISI or above cut off on the insomnia or CRD subscales of the SLEEP-50).
6 male, 5 female.
Mean age 18.9 years (SD = 1.9).
No control group.
8 sessions (10 week treatment window).
Individual.
Treatment techniques targeted both insomnia (eg stimulus control, sleep hygiene, relaxation) and circadian rhythm disruption (eg sleep/wake realignment, daily activity).
Treatment adaptations to account for developmental age and sleep architecture during adolescence are outlined. Within a residential rehabilitation setting, a four-session CBTi group intervention was evaluated in addition to usual care compared to usual care alone (Hwang et al., 2019) . This was a non-randomised, assessor blind trial with 63 patients. No significant changes in psychotic symptoms, depression or anxiety were found, although the study was underpowered. Significant improvements in sleep were reported posttreatment (4 weeks) and at follow-up (8 weeks). However, the effect sizes (ISI d = 0.8 at 8 weeks) were smaller than those reported in the BeST trial (ISI d = 1.9 at 12 weeks). This may indicate that longer treatment duration or individual rather than a group format is important for achieving large treatment effects.
(92%) completed
In acute settings, an assessor-blind pilot RCT of a novel sleep intervention has been conducted . Eighteen (45%) of the 40 participants, recruited from a single ward, had a diagnosis of non-affective psychosis. The intervention included CBTi, sleep monitoring, and light/dark exposure for circadian entrainment. In this acute setting the entire intervention was delivered in 2 weeks. Compared to usual care, there were large effect size reductions in insomnia (ISI d = 0.9) at post-treatment and follow-up (12 weeks). This was the only intervention study to report the outcome on negative symptoms: there was an indication of a small effect size improvement (d = 0.3), however the confidence intervals were wide, including zero, and so the findings are not conclusive. Patients who received the sleep intervention were discharged on average 8.5 days earlier.
One pilot RCT has evaluated imagery rehearsal training (IRT) to reduce nightmare severity in 24 patients with persecutory delusions (Sheaves et al., 2019) . In addition to IRT, the intervention included CBT techniques to target identified causal factors for nightmares, for example reducing worry and oversleeping. Large effect size improvements in nightmare severity (DDNSI d = 1.1) and insomnia (SCI d = 1.4) were reported post-treatment (4-weeks) and maintained at follow-up (8weeks). There was a medium effect size treatment benefit on paranoia favouring the CBT group at both 4 and 8 weeks. However, the confidence intervals are wide, hence a larger trial is required to estimate the effect with greater precision. There was no effect of the treatment on hallucinations which fits with the understanding that psychotic experiences are distinct phenomena with different causal factors (Peralta and Cuesta, 1999; Zavos et al., 2014) .
Discussion
There has been a sharp rise in the number of studies investigating sleep disruption and psychosis: the number of quantitative investigations has doubled in the last five years. There are numerous correlational studies, both in clinical and correlational studies, both in clinical and non-clinical studies, often substantial, that robustly support the cooccurrence of subjective sleep disruption and certain psychotic experiences across the spectrum of psychosis severity. Yet the mechanisms underpinning this relationship remain uncertain. Patient accounts consistently highlight the importance and negative impact of sleep problems and a desire for treatment. The principal advance has been the evaluation of adapted CBT for sleep disorders in patients with non-affective psychosis. The trials have generally been small, limiting the ability to determine the effect of improving sleep on psychotic experiences. Yet taken together an initial clinical picture forms: sleep disturbance is a common and treatable problem across the spectrum of psychosis severity that leads to small improvements in psychotic symptoms such as paranoia and hallucinations. To date, the OASIS trial provides the strongest test, showing that improving insomnia leads to improvements in paranoia and hallucinations. However, studies have been inadequately powered to test this in clinical populations.
There may be differences between how individual psychotic experiences are linked to distinct sleep disorders. In a study of 5000 adolescent twin pairs, the genetic and environmental influences of sleep disturbance were found to overlap with those for paranoia, hallucinations, and cognitive disorganisation but not grandiosity and anhedonia (Taylor et al., 2015) . In a robust experimental test of sleep restriction, negative affect was found to mediate the relationship between sleep loss and paranoia but not hallucinations . There are many plausible mechanisms, both psychological and biological, one might expect to underpin the association between sleep dysfunction and psychotic experiences. The most consistent evidence, at a psychological level, is for the role of negative affect mediating the association between insomnia and psychotic experiences (principally paranoia) (Freeman et al., 2009 Kasanova et al., 2019; Reeve et al., 2015; Reeve et al., 2018a) . Other potential routes include alexithymia, and dissociation, which could be further linked to adversity or trauma. Further work is needed to understand the mechanisms linking hallucinations and insomnia. Studies investigating the interaction of sleep problems with grandiosity, cognitive distortion, or negative symptoms are rare. This review has focused on psychological models, as this is the framework underpinning the first-line recommended treatment (CBTi), yet neurodevelopmental and neurochemical mechanisms are also plausible (Lunsford-Avery and Mittal, 2013) . For example, abnormalities in the interacting neurotransmitter systems and neural circuits observed in sleep and circadian disruption are also implicated in the aetiology of psychosis (Wulff et al., 2010) . At the neurobiological level, overactivity of dopamine receptors are implicated in both the causation of positive psychotic symptoms and wakefulness (Monti and Monti, 2005) . To date, we do not have clear evidence to indicate the primary route.
Understanding the mechanistic links will help in the adaptation and improvement of treatment, however it could be argued the key line of research needed now is how to provide the best evidence-based treatments for patients. Psychological interventions for sleep disturbance are applicable, feasible, and demonstrate large effect size improvements in insomnia and nightmares in patients with psychosis. This is consistent with the evidence-base for these treatments in other mental health disorders. The treatment is popular with patients with psychosis: the uptake rate is strikingly high (80-100%) and qualitative data indicate that patients value the opportunity to address sleep disturbance. The studies reporting the largest effect sizes made adaptations to standard treatment protocols. One key adaptation is the use of sleep restriction principles, without applying the formal sleep restriction protocol. In practice, this involves a degree of flexibility, sharing the aims of the procedure to reduce time in bed not sleeping and careful negotiation to set a 'sleep window'. This is particularly important given the experimental evidence for the impact of sleep restriction in the occurrence of psychotic experiences . Screening and evaluation of treatment progress can be achieved using brief self-report measures (for example, Insomnia Severity Index (Morin et al., 2011 )) yet they are infrequently used in current practice (Rehman et al., 2017) . Treatment protocols outlining adaptions for patients with psychosis have been produced (for example, Sheaves et al., 2018b; Waite et al., 2016b; Waite and Sheaves, 2020; Waters et al., 2017) . The next challenge is implementation.
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